KYMR
NASDAQKymera Therapeutics Inc.
News · 26 weeks136+163%
2026-01-182026-07-12
Mix8090d
- SEC Filings32(40%)
- Insider31(39%)
- Other10(13%)
- Leadership4(5%)
- Earnings2(3%)
- Analyst1(1%)
Latest news
25 items- INSIDERChief Executive Officer Mainolfi Nello exercised 50,000 shares at a strike of $2.08 and sold $5,950,000 worth of shares (50,000 units at $119.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- PRKymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 DegraderDr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Elizabeth Laws, Ph.D., as Senior Vice President, KT-621 Development Program Leader. Dr. Laws brings more than two decades of biopharmaceutical leaders
- INSIDERChief Business Officer Goodman Noah sold $387,329 worth of shares (3,389 units at $114.29) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 47,179 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Financial Officer Jacobs Bruce N. exercised 61,378 shares at a strike of $5.33 and sold $8,864,829 worth of shares (77,109 units at $114.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 244,883 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Executive Officer Mainolfi Nello sold $9,223,527 worth of shares (80,000 units at $115.29) as part of a pre-agreed trading plan and exercised 80,000 shares at a strike of $2.08 (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERAmendment: Director Booth Bruce sold $8,281,905 worth of shares (76,650 units at $108.05) as part of a pre-agreed trading plan (SEC Form 4)4/A - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERDirector Booth Bruce sold $3,424,800 worth of shares (31,283 units at $109.48) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERDirector Booth Bruce sold $56,460,136 worth of shares (513,245 units at $110.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Bvf Partners L P/Il sold $173,665,077 worth of shares (1,630,658 units at $106.50) (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kymera Therapeutics Inc.SCHEDULE 13D/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Booth Bruce sold $34,812,909 worth of shares (285,684 units at $121.86) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERDirector Booth Bruce sold $43,987,355 worth of shares (398,765 units at $110.31) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Bvf Partners L P/Il4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Booth Bruce4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Business Officer Goodman Noah exercised 5,000 shares at a strike of $21.05 and sold $570,000 worth of shares (5,000 units at $114.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Albers Jeffrey W.4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Hrustanovic Gorjan4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Esposito Pamela4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Maraganore John4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Director Sandor Victor4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
KYMR FAQ
7 questionsWhat does Kymera Therapeutics Inc. do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid...Where does KYMR stock trade?
Kymera Therapeutics Inc. (KYMR) is listed on NASDAQ.What sector and industry is KYMR in?
Kymera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kymera Therapeutics Inc. go public?
Kymera Therapeutics Inc. (KYMR) completed its IPO in 2020.What are analysts saying about KYMR?
Kymera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-05-06.What companies are similar to KYMR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KYMR side-by-side with any of them on Quantisnow.How can I track KYMR on Quantisnow?
Quantisnow aggregates Kymera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYMR to receive live email and push alerts on every new disclosure.